SCHEMBL30008722

SCHEMBL30008722

O=C(Cc1ccc(-c2ccnc3[nH]ccc23)cc1)N1CCCCC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 12/20 0.62
IKBKB O14920 3/20 0.56
CHUK O15111 3/20 0.56
NEK1 Q96PY6 3/20 0.53
CIT O14578 2/20 0.48
DAPK3 O43293 1/20 0.48
JAK2 O60674 1/20 0.48
PRKD3 O94806 1/20 0.48
MAP4K4 O95819 1/20 0.48
PAK4 O96013 1/20 0.48
CSF1R P07333 1/20 0.48
RET P07949 1/20 0.48
IGF1R P08069 1/20 0.48
FGFR1 P11362 1/20 0.48
PRKACA P17612 1/20 0.48
FLT1 P17948 1/20 0.48
LTK P29376 1/20 0.48
GRK5 P34947 1/20 0.48
KDR P35968 1/20 0.48
MAP2K2 P36507 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30009139 0.99 JAK1 (0.61) JAK1IKBKBCHUKNEK1CIT
SCHEMBL30009807 0.97 JAK1 (0.61) JAK1IKBKBCHUKNEK1CIT
SCHEMBL30009063 0.91 ROCK2 (0.54) JAK1IKBKBCHUKNEK1CIT
SCHEMBL30009207 0.89 JAK1 (0.53) JAK1IKBKBCHUKNEK1CIT
SCHEMBL30008764 0.89 JAK1 (0.63) JAK1IKBKBCHUKNEK1CIT
SCHEMBL30009468 0.89 JAK1 (0.63) JAK1IKBKBCHUKNEK1PRKAA1
SCHEMBL30009811 0.89 JAK1 (0.63) JAK1IKBKBCHUKNEK1CIT
SCHEMBL30009818 0.87 JAK1 (0.52) JAK1IKBKBCHUKNEK1CIT
SCHEMBL30009454 0.84 JAK1 (0.68) JAK1IKBKBCHUKJAK2JAK3
SCHEMBL857458 0.82 IKBKB (0.63) IKBKBCHUKNEK1CITDAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US claimed
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor MAP3K20, MAP3K15, MAP3K1 JAK1 83/4885IKBKB 294/4885CHUK 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.